csirt@kutim:~/threat-intel/cve/CVE-2022-31064

Katalog CVE

CVSS 5.4 · Medium EPSS 1,3%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') pada bigbluebutton. Skor CVSS 3.1 5.4 (Medium) menurut NVD.

Deskripsi (NVD)

BigBlueButton is an open source web conferencing system. Users in meetings with private chat enabled are vulnerable to a cross site scripting attack in affected versions. The attack occurs when the attacker (with xss in the name) starts a chat. in the victim's client the JavaScript will be executed. This issue has been addressed in version 2.4.8 and 2.5.0. There are no known workarounds for this issue.

Rincian

Terbit di NVD
27 Juni 2022
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
5.4 (Medium), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
EPSS (30 hari)
1,3% peluang dieksploitasi; lebih tinggi dari 69,0% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
bigbluebutton bigbluebutton Versi 2.4 hingga sebelum 2.4.8
bigbluebutton bigbluebutton Versi 2.3.0
bigbluebutton bigbluebutton Versi 2.4.9
bigbluebutton bigbluebutton Versi 2.5 alpha1
bigbluebutton bigbluebutton Versi 2.5 alpha2
bigbluebutton bigbluebutton Versi 2.5 alpha3
bigbluebutton bigbluebutton Versi 2.5 alpha4
bigbluebutton bigbluebutton Versi 2.5 alpha5
bigbluebutton bigbluebutton Versi 2.5 alpha6
bigbluebutton bigbluebutton Versi 2.5 beta1
bigbluebutton bigbluebutton Versi 2.5 beta2
bigbluebutton bigbluebutton Versi 2.5 rc.1
bigbluebutton bigbluebutton Versi 2.5 rc.2
bigbluebutton bigbluebutton Versi 2.5 rc.3
bigbluebutton bigbluebutton Versi 2.5 rc.4

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.